310 related articles for article (PubMed ID: 28604143)
1. Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model.
Meng X; Du G; Ye L; Sun S; Liu Q; Wang H; Wang W; Wu Z; Tian J
Int J Immunopathol Pharmacol; 2017 Sep; 30(3):215-226. PubMed ID: 28604143
[TBL] [Abstract][Full Text] [Related]
2. Comparison study of different indoleamine-2,3 dioxygenase inhibitors from the perspective of pharmacodynamic effects.
Jiang X; Li X; Zheng S; Du G; Ma J; Zhang L; Wang H; Tian J
Int J Immunopathol Pharmacol; 2020; 34():2058738420950584. PubMed ID: 32962460
[TBL] [Abstract][Full Text] [Related]
3. NLG919/cyclodextrin complexation and anti-cancer therapeutic benefit as a potential immunotherapy in combination with paclitaxel.
Xu J; Ren X; Guo T; Sun X; Chen X; Patterson LH; Li H; Zhang J
Eur J Pharm Sci; 2019 Oct; 138():105034. PubMed ID: 31382032
[TBL] [Abstract][Full Text] [Related]
4. Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapy.
Sun J; Wan Z; Chen Y; Xu J; Luo Z; Parise RA; Diao D; Ren P; Beumer JH; Lu B; Li S
Acta Biomater; 2020 Apr; 106():289-300. PubMed ID: 32004652
[TBL] [Abstract][Full Text] [Related]
5. PCC0208009 enhances the anti-tumor effects of temozolomide through direct inhibition and transcriptional regulation of indoleamine 2,3-dioxygenase in glioma models.
Sun S; Du G; Xue J; Ma J; Ge M; Wang H; Tian J
Int J Immunopathol Pharmacol; 2018; 32():2058738418787991. PubMed ID: 29993291
[TBL] [Abstract][Full Text] [Related]
6. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H
J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389
[TBL] [Abstract][Full Text] [Related]
7. An albumin-bound drug conjugate of paclitaxel and indoleamine-2,3-dioxygenase inhibitor for enhanced cancer chemo-immunotherapy.
Hu Z; Zheng B; Xu J; Gao S; Lu W
Nanotechnology; 2020 May; 31(29):295101. PubMed ID: 32203949
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.
Hou DY; Muller AJ; Sharma MD; DuHadaway J; Banerjee T; Johnson M; Mellor AL; Prendergast GC; Munn DH
Cancer Res; 2007 Jan; 67(2):792-801. PubMed ID: 17234791
[TBL] [Abstract][Full Text] [Related]
9. Nano-encapsulated tryptanthrin derivative for combined anticancer therapy via inhibiting indoleamine 2,3-dioxygenase and inducing immunogenic cell death.
Yang C; He B; Zheng Q; Wang D; Qin M; Zhang H; Dai W; Zhang Q; Meng X; Wang X
Nanomedicine (Lond); 2019 Sep; 14(18):2423-2440. PubMed ID: 31549585
[No Abstract] [Full Text] [Related]
10. Astragaloside IV inhibits progression of lung cancer by mediating immune function of Tregs and CTLs by interfering with IDO.
Zhang A; Zheng Y; Que Z; Zhang L; Lin S; Le V; Liu J; Tian J
J Cancer Res Clin Oncol; 2014 Nov; 140(11):1883-90. PubMed ID: 24980548
[TBL] [Abstract][Full Text] [Related]
11. Computational study on new natural compound inhibitors of indoleamine 2,3-dioxygenase 1.
Jiang S; Li H; Piao L; Jin Z; Liu J; Chen S; Liu LL; Shao Y; Zhong S; Wu B; Li W; Ren J; Zhang Y; Wang H; Jin R
Aging (Albany NY); 2020 Jun; 12(12):11349-11363. PubMed ID: 32568737
[TBL] [Abstract][Full Text] [Related]
12. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.
Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D
J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064
[TBL] [Abstract][Full Text] [Related]
13. The enhanced antitumour response of pimozide combined with the IDO inhibitor L‑MT in melanoma.
Jia H; Ren W; Feng Y; Wei T; Guo M; Guo J; Zhao J; Song X; Wang M; Zhao T; Wang H; Feng Z; Tian Z
Int J Oncol; 2018 Sep; 53(3):949-960. PubMed ID: 30015838
[TBL] [Abstract][Full Text] [Related]
14. An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy.
Chen Y; Xia R; Huang Y; Zhao W; Li J; Zhang X; Wang P; Venkataramanan R; Fan J; Xie W; Ma X; Lu B; Li S
Nat Commun; 2016 Nov; 7():13443. PubMed ID: 27819653
[TBL] [Abstract][Full Text] [Related]
15. PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice.
Hu Z; Yu P; Du G; Wang W; Zhu H; Li N; Zhao H; Dong Z; Ye L; Tian J
PLoS One; 2020; 15(3):e0228339. PubMed ID: 32214351
[TBL] [Abstract][Full Text] [Related]
16. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.
Holmgaard RB; Zamarin D; Munn DH; Wolchok JD; Allison JP
J Exp Med; 2013 Jul; 210(7):1389-402. PubMed ID: 23752227
[TBL] [Abstract][Full Text] [Related]
17. Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy. Laboratory investigation.
Miyazaki T; Moritake K; Yamada K; Hara N; Osago H; Shibata T; Akiyama Y; Tsuchiya M
J Neurosurg; 2009 Aug; 111(2):230-7. PubMed ID: 19199463
[TBL] [Abstract][Full Text] [Related]
18. Nanoconjugates to enhance PDT-mediated cancer immunotherapy by targeting the indoleamine-2,3-dioxygenase pathway.
Yang X; Zhang W; Jiang W; Kumar A; Zhou S; Cao Z; Zhan S; Yang W; Liu R; Teng Y; Xie J
J Nanobiotechnology; 2021 Jun; 19(1):182. PubMed ID: 34127005
[TBL] [Abstract][Full Text] [Related]
19. Curcumin combined with FAPαc vaccine elicits effective antitumor response by targeting indolamine-2,3-dioxygenase and inhibiting EMT induced by TNF-α in melanoma.
Jiang GM; Xie WY; Wang HS; Du J; Wu BP; Xu W; Liu HF; Xiao P; Liu ZG; Li HY; Liu SQ; Yin WJ; Zhang QG; Liang JP; Huang HJ
Oncotarget; 2015 Sep; 6(28):25932-42. PubMed ID: 26305550
[TBL] [Abstract][Full Text] [Related]
20. Uveal melanoma expression of indoleamine 2,3-deoxygenase: establishment of an immune privileged environment by tryptophan depletion.
Chen PW; Mellon JK; Mayhew E; Wang S; He YG; Hogan N; Niederkorn JY
Exp Eye Res; 2007 Nov; 85(5):617-25. PubMed ID: 17870068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
